JAK Inhibitor Deal Benchmarks in Gastroenterology

Median Upfront

$565M

Range: $302M - $818M

Total Deal Value

$2.9B

Range: $1.8B - $3.9B

Royalty Rate

7.8% - 14.5%

Tiered up to 18.5%

Dev Milestones

$486M

Range: $318M - $656M

Model Your Deal

Market Analysis

JAK Inhibitor therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 jak inhibitor asset in gastroenterology is $565M, with total deal values reaching $2.9B. Development milestones average $486M, while regulatory milestones contribute $579M.

The gastroenterology jak inhibitor landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for jak inhibitor gastroenterology deals range from 7.8% to 14.5% at the base tier, with tiered escalation reaching 11.8%-18.5% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a jak inhibitor gastroenterology licensing deal?

Based on our analysis, Phase 2 jak inhibitor licensing deals in gastroenterology average $565M in upfront payments, with a range of $302M to $818M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for jak inhibitor gastroenterology transactions?

The median total deal value for Phase 2 jak inhibitor assets in gastroenterology is $2.9B, ranging from $1.8B to $3.9B. This includes development milestones ($486M), regulatory milestones ($579M), and commercial milestones ($1.3B).

What royalty rates are standard for jak inhibitor deals in gastroenterology?

Base royalty rates for jak inhibitor gastroenterology transactions range from 7.8% to 14.5%, with tiered escalations reaching 11.8%-18.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in jak inhibitor gastroenterology deals?

JAK Inhibitor gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($486M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($579M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

JAK Inhibitor Deal Benchmarks in Gastroenterology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Gastroenterology

Monoclonal Antibody in Gastroenterology

JAK Inhibitor in Immunology & Autoimmune

JAK Inhibitor in Dermatology

Ready to Calculate Your Deal Terms?